Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Cisplatin TACE for HCC
NCT02821533Phase 2Terminated
- Sponsor
- The Chinese University of Hong Kong
- Start
- Feb 2012
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin in hepatocellular carcinoma (HCC), sponsored by The Chinese University of Hong Kong. Started Feb 2012; status: terminated.
02
Drugs
cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02821533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821533.